2026 年 1 月 11 日（旧金山洲际旅馆）——我们很兴奋地宣布，，，，，yl23455永利将受邀在 雅法 ACCESS ASIA 药通亚洲 BD 论坛 @ JPM 2026 上发演出讲。。。。。。
January 11, 2026 (InterContinental San Francisco) — We’re pleased to announce that Medicilon to speak at YAFO ACCESS ASIA BD Forum @ JPM 2026.
由雅法主理的ACCESS ASIA论坛，，，，，延续ACCESS CHINA的乐成履历，，，，，将亚洲领先的生物科技跨境平台拓展至更辽阔领域，，，，，毗连立异者与全球药企、投资机构和战略相助同伴。。。。。。论坛将于2026年1月11日在旧金山洲际旅馆举行，，，，，为亚洲生物科技企业提供全球舞台，，，，，展示立异效果，，，，，促成战略相助，，，，，开拓商业生长新机缘。。。。。。更多信息请会见：https://biotochina.org/
ACCESS ASIA, hosted by YAFO, builds on the success of ACCESS CHINA, expanding Asia’s leading cross-border biotech platform to connect innovators with global pharma, investors, and strategic partners.Taking place on January 11, 2026, at the InterContinental San Francisco, the forum provides a global stage for Asian biotech companies to showcase their innovation, foster partnerships, and explore new business development opportunities.
View more information at: https://biotochina.org/
演讲嘉宾
About the speaker
陈春麟博士 Dr. Chunlin Chen
首创人、董事长兼CEO Founder, Chairman and CEO
1986年结业于中国药科大学,获药学硕士学位并于1994年结业于美国俄克拉何马州立大学，，，，，获药理学及毒理学博士学位，，，，，中欧商学院EMBA。。。。。。结业后从事多年药物的药理、毒理及生物化学研究，，，，，在设计心血管药物、抗艾滋和抗癌新药的药代动力学和代谢方面有着很深的造诣。。。。。。2004年头回国开办yl23455永利。。。。。。公司已经为2000多家biotech、制药公司及大学和研究所提供新药研发效劳，，，，，并资助和支持凌驾580件立异药IND在中国、美国、澳大利亚、欧盟和韩国等获批进入临床研究。。。。。。现担当中国药理学会药物代谢动力学专业委员会委员、上海西欧同砚会生物医药分会会长及上海浦东生物医药协会副理事长等职务，，，，，同时还受聘为中国药科大学生命科学院客座教授。。。。。。小我私家殊荣有：浦东新区“创业人才”奖(2005年)；；；；上海市浦江人才(2007年)；；；；上海市领武士才(2009年)；；；；上海“归国创业精英奖(2009年)；；；；国务院约请的北戴河休假专家(2009年)；；；；上海市优异手艺带动人(2011年)；；；；上海张江高新手艺工业开发区建设突出孝顺小我私家(2011年)；；；；获得常州市“龙城英才妄想”领武士才(2012年)；；；；上海高科技园区“最热情药谷人奖”。。。。。。
Dr. Chen is Chairman, founder and CEO of Medicilon. Medicilon’s core business is to provide preclinical chemistry, ADMET and biology services to pharmaceutical companies and biotech companies. Prior to founding Medicilon, Dr. Chen had work experience in the USA, as a Staff Investigator at Department of Pharmacokinetics and Metabolism in Vertex Pharmaceuticals and as the Director of Pharmaceutical Department at Parker Hughes Cancer Center.In addition, Dr. Chen currently serves as Associate Director for Pharmacokinetics and Drug Metabolism Section of Shanghai Pharmacology Society and visiting Professor for China Pharmaceutical University. Dr. Chen got several awards including Excellent Teacher Award from China Pharmaceutical University, Research Excellent Award from Oklahoma State University. Medicilon has provided drug development services to over 2,000 clients worldwide and has assisted in the approval of 588 IND applications for clinical trials globally.
蔡金娜博士 Dr. Jinna Cai
首席商务官 Chief Business Officer
本科硕士博士均结业于中国药科大学，，，，，博士时代曾在日本富山医科药科大学和汉药研究所资源开发部加入所作研究，，，，，随后在中科院上海药物所博士后流动站事情，，，，，有30多年中药新药和化学药产品开发研究履历。。。。。。曾于1991年荣获国家中医药治理局科学手艺前进一等奖，，，，，1992年荣获国家科学手艺前进一等奖。。。。。。此后在汇仁集团研发部任研究中心主任，，，，，荣获2004年汇仁公司“十佳”女员工和2006年被江西省经贸委评为“十五”全省企业手艺中心治理先进小我私家。。。。。。后于2008年7月加入yl23455永利，，，，，先后任中国区市场开拓总监、副总裁、商务生长部副总裁。。。。。。
Dr. Cai completed her whole high-level education at China Pharmaceutical University from Bachelor to Ph.D. Conducted research with Medical University of Toyama and Institution of Natural Medicine cooperatively. Later, she worked at Chinese Academy of Sciences Shanghai Institute of Materia Medica.
Over 30 years of dedication in new drug development and research. Was awarded the first Prize for Science and Technology Progress by the State Administration of Traditional Chinese Medicine in 1991 and National Awards for Science and Technology Grade I in 1992. Worked for Huiren Group as director of R&D Center for 5 years. Was awarded one of the top 10 employees by Huiren Group in 2006 and Excellent Management Individual of Provincial Technological Center during the “10th-five-year “by Jiangxi Province.
Dr. Cai joined Medicilon in July 2008 and took on the position of BD Head of Chinese market and then Vice President of BD Department.
林庆聪博士 Dr. Qingcong Lin
执行副总裁兼美国公司总裁 President at Medicilon USA Corp
美国纽约爱因斯坦医学院分子细胞生物学博士，，，，，曾一连四年荣获“SAPA-NE效劳奖”，，，，，获评“北京外洋人才”、“南京大学优异青年西席”等声誉称呼。。。。。。
林博士学术配景深挚，，，，，曾在美国阿尔伯特·爱因斯坦医学院Raju Kucherlapati’s 实验室、哈佛大学医学院从事分子遗传学研究等，，，，，曾任哈佛大学医学院遗传和基因组学研究中心基因工程实验室总监，，，，，在MCB、JBC等国际权威期刊上揭晓24篇论文，，，，，并荣获多项发明专利。。。。。。多年学术浸润，，，，，使他在细胞生物学、分子生物学、免疫学、药理学、抗体药物发明和开发、发育生物学、生物信息学以及功效遗传学和基因组学等领域沉淀了极高的学术造诣和扎实的手艺功底。。。。。。
深耕生物医药研发领域近40载，，，，，林博士不但在学术界爆发了主要影响，，，，，也为全球生物医药行业的生长做出了卓越孝顺，，，，，曾为跨国公司创立子公司，，，，，组建多个科学团队，，，，，向导百余个药物项目研发，，，，，在细胞生物学、分子遗传学、基因工程的肿瘤小鼠模子研究与应用领域颇有研究，，，，，在抗体药物研发、杂交瘤细胞抗体和人噬菌体抗体库的建设、抗体基因工程、抗体人源化和亲和力提高与成熟，，，，，以及哺乳动物细胞抗体药物生产上, 积累了富厚的项目开发履历和治理智慧。。。。。。加入yl23455永利之前，，，，，林博士曾担当惠氏制药资深科学家Ⅱ级、首席科学家Ⅰ级和Ⅱ级以及分子遗传学实验室主任；；；；辉瑞制药首席科学家Ⅱ级；；；；盛诺基医药生物和抗体药物研发资深副总裁；；；；百奥赛图资深副总裁兼Biocytogen Boston Corp（BBC）首席执行官等。。。。。。
Dr. Qingcong Lin holds a Ph.D. in Molecular Biology from the Albert Einstein College of Medicine of Yeshiva University. He has conducted molecular genetics research in Raju Kucherlapati’s laboratory at Albert Einstein College of Medicine and Harvard Medical School. He has served as the Director of the Gene Modification Laboratory at Harvard-Partners Center for Genetics and Genomics (HPCGG). He has also published 24 papers in prestigious international journals such as MCB, JBC and holds multiple invention patents.
Having worked in the pharmaceutical R&D field for nearly 40 years, Dr. Lin has not only made significant impacts in academics but also contributed remarkably to the global pharmaceutical industry. Before joining Medicilon, Dr. Lin held positions such as Senior Scientist II, Principal Research Scientist I & II, and Director of Molecular Genetics Laboratory at Wyeth Research; Principal Research Scientist II and Group Leader at Pfizer Research; Senior VP of Biology and Antibody R&D at Shenogen Pharma Group; and SVP of Beijing Biocytogen, CEO of Biocytogen Boston Corp.
Dr. Lin has established subsidiary companies for multinational corporations, built multiple scientific teams, and has excellent drug R&D experience gained in more than 100 projects. Dr. Lin has accumulated rich experience in project development and management in antibody drug development, establishment of hybridoma cell antibodies and human phage antibody libraries, antibody gene engineering, antibody humanization, affinity maturation, and mammalian cell antibody drug production.
段茂圣博士 Dr. Maosheng Duan
药物发明事业部兼药学研究事业部总裁 President of Drug Discovery and CMC Divisions
南开大学有机化学硕士，，，，，美国俄亥俄州立大学 （The Ohio State University）生物化学硕士，，，，，有机化学博士，，，，，国家级外洋高条理专家；；；；横跨国际大型药企、CRO和Biotech手艺公司，，，，，在生物医药领域耕作25年，，，，，积累了研发、运营和治理的富厚履历。。。。。。
段博士亲自主持了从立项、PCC、IND研究和申报、直至临床研究的全链条药物研发。。。。。。不但明确药物开发流程，，，，，并且普遍涉猎药物化学、CMC、生物学、药理学、药代动力学、毒理学等多个领域，，，，，掌握种种数据解读，，，，，增进高效决议。。。。。。别的，，，，，作为焦点治理者，，，，，段博士善于向导跨部分、跨学科团队协作，，，，，有用整合多方资源，，，，，推进研发管线，，，，，在抗病毒、抗肿瘤、代谢性疾病、免疫学等疾病领域划分将多个分子推进到 IND和临床研究的差别阶段，，，，，并有两款药物获得FDA批准上市。。。。。。段博士跟紧生物医药手艺前沿，，，，，对共价抑制剂，，，，，ADC，，，，，PROTAC、小核酸等领域有着深刻的看法。。。。。。段博士拥有34项发明专利，，，，，并在权威学术期刊上揭晓了28篇经由偕行评审的高质量学术论文。。。。。。
加入yl23455永利之前，，，，，段博士曾任GSK首席科学家，，，，，积累了10年小分子药物研发履历；；；；在辉源生物担当副总裁时代，，，，，完成从0-1构建药物化学效劳部，，，，，为海内外药企提供了强有力的药物研发支持直至公司被药明康德收购。。。。。。因此，，，，，深谙CRO“质量-效率-交付”的效劳宗旨；；；；作为越之康泰生物的配合首创人、首席执行官及首席科学官，，，，，向导公司运营、研发及临床开发，，，，，乐成推动了公司资产在2020年被收购；；；；在纳肽得生物担当首席执行官时代，，，，，主导小核酸(siRNA)手艺平台建设和项目管线开发，，，，，并通过商务BD，，，，，乐成完成了管线对外授权（license out）和生意。。。。。。这些富厚履历和卓越成绩，，，，，将为yl23455永利的生长注入强劲动力。。。。。。
Dr. Maosheng Duan holds a Master’s degree in Organic Chemistry from Nankai University in Tianjin, China, as well as a Ph.D. in Organic Chemistry and a Master’s degree in Biochemistry from The Ohio State University in the USA. With over 25 years of experience in the pharmaceutical and biotech industry, Dr. Duan has worked across international big pharma, CROs, and biotech companies, gaining extensive expertise in R&D, operations, and management. Prior to joining Medicilon, Dr. Duan held key leadership roles at prominent organizations, including GSK, HD Biosciences, YueZhi KangTai Biomedicine, and NanoPeptide Biotechnology.
Dr. Duan has directed and led the entire drug research and development process, from project initiation and PCC nomination to IND enabling, filing, and clinical studies. He possesses not only a broad understanding of the drug R&D process but also deep expertise in medicinal chemistry, CMC, biology, pharmacology, pharmacokinetics, toxicology, and clinical regulations. Additionally, Dr. Duan is highly skilled in interpreting diverse types of data to facilitate efficient decision-making.
As a core leader, Dr. Duan excels in guiding cross-functional and interdisciplinary teams, effectively integrating resources to advance R&D pipelines. He has successfully progressed multiple molecules through various stages, from IND filings to clinical studies and NDAs, in the fields of antiviral, antitumor, metabolic diseases, and immunology, with two FDA-approved drugs. Dr. Duan remains at the forefront of biomedical technologies, offering unique insights into cutting-edge areas such as covalent inhibitors, ADCs, PROTACs, and RNAi. His accomplishments include 34 invention patents and 28 publications in peer-reviewed journals.
关于ACCESS ASIA药通亚洲 BD Forum @ JPM 2026
2026 年 1 月 11 日，，，，， ACCESS ASIA 药通亚洲BD论坛 @ JPM 2026 将在美国旧金山洲际旅馆正式举行。。。。。。
ACCESS ASIA BD Forum @ JPM is scheduled to be held on January 11, 2026, at the InterContinental San Francisco, alongside the J.P. Morgan Healthcare Conference Week.
本次为期一天的论坛将泛起主题演讲、圆桌讨论、企业路演、公司展示，，，，，以及 1 对 1 相助洽谈，，，，，旨在毗连亚洲领先的生物科技立异者与全球制药公司、投资机构及战略相助同伴。。。。。。
This full-day forum will feature keynote speeches, panel discussions, corporate presentations, company showcases, and 1-on-1 partnering meetings connecting Asia’s leading biotech innovators with global pharma, investors, and strategic partners.
聚会名称:ACCESS ASIA 药通亚洲BD论坛 @ JPM 2026
时间 & 所在: 2026 年 1 月 11 日 | 旧金山洲际旅馆
更多活动详情请至: https://biotochina.org/
扫描二维码注册
